Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 80

Sort by

Sort Order Select

Journal Articles

Short-term and long-term sting activation elicit divergent cellular responses in distinct hematopoietic populations in chronic myelomonocytic leukemia

Yue Wei, Xiaoping Su, Ziyi Li, Sanam Loghavi, Hui Yang, Hong Zheng, Kirbie Linthicum, Vicky A. Appleman, Tiquella Hatten, Harry Huang, Jeffrey Raizer, Alex Parent, Neil Lineberry, Siddha Kasar, Guillermo Garcia-Manero, Guillermo Montalban-Bravo

Blood (2025) 146 (Supplement 1): 3832.

https://doi.org/10.1182/blood-2025-3832

Published: 2025

Journal Articles

Allergin-1 marks leukemic stem cells and enables immune evasion in AML: A target for therapeutic antibody development

Yi Pan, Lijun Mu, Chen Wang, Wenxuan Zhou, Xiaduo Meng, Jie Jia, Dandan Wang, Xiaohong Wang, Lingrui Song, Haoyu Wang, Zhaoming Guo, Kun Ma, Mi Deng, Richard Hammer, Hong Zheng, Gerhard Hildebrandt, Xunlei Kang, Changhao Cui

Blood (2025) 146 (Supplement 1): 1455.

https://doi.org/10.1182/blood-2025-1455

Published: 2025

Journal Articles

A defined culture model for ex vivo expansion of primary AML cells preserves leukemic stem cells and clonal architecture for functional and therapeutic studies

Charyguly Annageldiyev, Upendar Golla, Satyam Patel, Rebecca Gelfer, Joseph Cioccio, Kentaro Minagawa, Hong Zheng, Su-Fern Tan, David Feith, Thomas Loughran, Ross Levine, Arati Sharma, David Claxton

Blood (2025) 146 (Supplement 1): 3488.

https://doi.org/10.1182/blood-2025-3488

Published: 2025

Journal Articles

Prospective study of patient-reported depression, and cognitive and functional impairment, and impact on survival and induction mortality in fit adults age ≥60 years receiving intensive chemotherapy (IC) for Acute Myeloid Leukemia (AML): Prospective geriatric assessment (GA) report from ECOG-ACRIN (EA) E2906 randomized study

Blood (2025) 146 (Supplement 1): 882.

https://doi.org/10.1182/blood-2025-882

Published: 2025

Journal Articles

Study on the efficacy and safety of HDAC inhibitor combined with venetoclax and azacitidine in the treatment of adult T-ALL

Jiyi Fu, Boyue Zheng, Jun Wang, Jiafei Wu, Hong Zheng, Xiaobing Huang, Xi Yang, Li Hui

Blood (2025) 146 (Supplement 1): 1579.

https://doi.org/10.1182/blood-2025-1579

Published: 2025

Journal Articles

Hypomethylation agent improves late-stage megakaryocyte maturation in MDS

Yue Wei, Yue Lyu, Koji Sasaki, Ziyi Li, Hong Zheng, Yue Lu, Marcos Estecio, Abhinav Jain, Hui Yang, Kelly Chien, Ian Bouligny, Guillermo Garcia-Manero

Blood (2025) 146 (Supplement 1): 196.

https://doi.org/10.1182/blood-2025-196

Published: 2025

Journal Articles

Leonurine significantly enhance the activity of dendritic cells derived from chronic myeloid Leukemia Patients

Xueqing Wang, Yifan Wang, Xiaodong Wang, Hu Zhang, Xiaobing Huang, Lin He, Hong Zheng, Jingying Dai

Blood (2025) 146 (Supplement 1): 7308.

https://doi.org/10.1182/blood-2025-7308

Published: 2025

Journal Articles

Oncofetal RNA-binding proteins IGF2BP suppress innate immunity signaling pathways in leukemia stem cells

Garrett Knox, Ruba Agili-Shaban, Alexis Morrissey, Karamveer Karamveer, Ahsan Polash, Stefanija Kinzy, Maria Wohlbowne, Cheryl Keller, George-Lucian Moldovan, Arati Sharma, Hong Zheng, Edward Harhaj, Markus Hafner, Zhenqiu Liu, Yasin Uzun, Shaun Mahony, Irina Elcheva

Blood (2025) 146 (Supplement 1): 3236.

https://doi.org/10.1182/blood-2025-3236

Published: 2025

Journal Articles

Real-world efficacy and prognostic modeling of venetoclax-enhanced intensive chemotherapy in fit AML

Boyue Zheng, Jiyi Fu, Jiafei Wu, Xiaobing Huang, Hong Zheng, Xi Yang, Li Hui

Blood (2025) 146 (Supplement 1): 6985.

https://doi.org/10.1182/blood-2025-6985

Published: 2025

Journal Articles

Boosting anti-tumor immunity in NRAS;ASXL1-driven Acute Myeloid Leukemia through combined inhibition of MEK and HDACs.

Meher Gayatri Bolisetti, Anthony Veltri, Jacqueline Cook, Bei Jia, Jing Li, Maoshou Yang, Vysakh Anandan, Jiacheng Yao, Kenneth Man Chan, Sarah Granozio, Esraa Keewan, Erik Ranheim, Xiaolan Zhu, Kalyan Nadiminti, Suresh Marulasiddappa, Hong Zheng, Xiaona You, Jing Zhang

Blood (2025) 146 (Supplement 1): 5007.

https://doi.org/10.1182/blood-2025-5007

Published: 2025

Journal Articles

Single-center retrospective analysis of venetoclax-based triple-drug combination therapy for relapsed Acute Myeloid Leukemia post allogeneic hematopoietic stem cell transplantation.

Xi Yang, cheng Li, Yu Wang, Hong Zheng, Xuemei Ye, Xiaobing Huang

Blood (2025) 146 (Supplement 1): 7808.

https://doi.org/10.1182/blood-2025-7808

Published: 2025

Journal Articles

The venetoclax combined with metronomic low-dose decitabine and interferon for preventing post-transplant relapse in high-risk MDS and AML patients

Xi Yang, chenglong Li, Hong Zheng, Xiaobing Huang

Blood (2025) 146 (Supplement 1): 7793.

https://doi.org/10.1182/blood-2025-7793

Published: 2025

Journal Articles

The single-center retrospective analysis of steroid-free rmap regimen (ruxolitinib, montelukast, azithromycin, and pirfenidone) treating moderate-to-severe bronchiolitis obliterans syndrome (BOS).

Xi Yang, chenglong Li, Hong Zheng, qian Wang, hang Zhang, Xiaobing Huang

Blood (2025) 146 (Supplement 1): 2507.

https://doi.org/10.1182/blood-2025-2507

Published: 2025

Journal Articles

Efficacy and prognosis of venetoclax combined with the 3+7 regimen in fit AML: A propensity score-matched cohort study

Boyue Zheng, Jiyi Fu, Jun Wang, Jiafei Wu, Xi Yang, Xiaobing Huang, Hong Zheng, Li Hui

Blood (2025) 146 (Supplement 1): 3463.

https://doi.org/10.1182/blood-2025-3463

Published: 2025

Journal Articles

Venetoclax Plus Chidamide/Azacitidine Dual Epigenetic Target Regimen in High-Risk Acute Lymphoblastic Leukemia: Preclinical and Case Series Studies

Boyue Zheng, FU JIyi, Wang Yijing, Wang Yu, Wang Huan, Yang Haiqing, Yang XI, Hong Zheng, Li Hui

Blood (2024) 144 (Supplement 1): 5894.

https://doi.org/10.1182/blood-2024-202512

Published: 2024

Journal Articles

Human IFN-α2- and PD-L1-Modified T Cells (αp-T cells) Inhibit Graft-Versus-Host Disease but Retain Anti-Leukemia Activity

Yuanyuan Tian, Bei Jia, Che Young Lee, Qingrong Huang, Chenchen Zhao, Ciril Abraham, Wenbin Mo, Mimi Chen, Ying WANG, Hong Zheng, Yi Zhang

Blood (2024) 144 (Supplement 1): 87.

https://doi.org/10.1182/blood-2024-203954

Published: 2024

Journal Articles

Efficacy and Safety of Dose-Tailored Mitoxantrone Liposomes Combined with Cytarabine and Venetoclax in Newly Diagnosed Acute Myeloid Leukemia (Non-M3) Based on Marrow Leukemic Cellularity

Li Hui, FU JIyi, Boyue Zheng, Lianjie HU, Yaqiong LI, Xin WANG, Qing HU, Li Wei, Hai Yi, Ying Yuan, Wang Huan, Yang Haiqing, Xi Yang, Hong Zheng, Yongqian Jia

Blood (2024) 144 (Supplement 1): 6068.

https://doi.org/10.1182/blood-2024-203401

Published: 2024

Journal Articles

Exploring Prognostic Factors of Venetoclax Combined with Azacitidine in Unfit AML Based on Real-World Data from a Chinese Population

Boyue Zheng, FU JIyi, Jiafei Wu, Wang Yu, Jun Wang, Chuanyan Jiang, Wang Huan, Yang Haiqing, Xi Yang, Hong Zheng, Li Hui

Blood (2024) 144 (Supplement 1): 5948.

https://doi.org/10.1182/blood-2024-205623

Published: 2024

Journal Articles

Risk Factors for CMV Infection, Including HLA Disparity and Ptcy Transplant in the Era of Letermovir Prophylaxis

Blood (2023) 142 (Supplement 1): 4914.

https://doi.org/10.1182/blood-2023-187917

Published: 2023

Journal Articles

Sting-Mediated Interferon Signaling Exerts Potent Antileukemic Effects in High-Risk Myeloid and Monocytic Malignancies

Yue Wei, Ziyi Li, Hui Yang, Hong Zheng, Vicky Appleman, Tiquella Hatten, Yu-Chung Huang, Jeffrey Raizer, Alex Parent, Neil Lineberry, Guillermo Garcia-Manero, Guillermo Montalban-Bravo

Blood (2023) 142 (Supplement 1): 3212.

https://doi.org/10.1182/blood-2023-177985

Published: 2023

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Short-term and long-term sting activation elicit divergent cellular responses in distinct hematopoietic populations in chronic myelomonocytic leukemia

Allergin-1 marks leukemic stem cells and enables immune evasion in AML: A target for therapeutic antibody development

A defined culture model for ex vivo expansion of primary AML cells preserves leukemic stem cells and clonal architecture for functional and therapeutic studies

Study on the efficacy and safety of HDAC inhibitor combined with venetoclax and azacitidine in the treatment of adult T-ALL

Hypomethylation agent improves late-stage megakaryocyte maturation in MDS

Leonurine significantly enhance the activity of dendritic cells derived from chronic myeloid Leukemia Patients

Oncofetal RNA-binding proteins IGF2BP suppress innate immunity signaling pathways in leukemia stem cells

Real-world efficacy and prognostic modeling of venetoclax-enhanced intensive chemotherapy in fit AML

Boosting anti-tumor immunity in NRAS;ASXL1-driven Acute Myeloid Leukemia through combined inhibition of MEK and HDACs.

Single-center retrospective analysis of venetoclax-based triple-drug combination therapy for relapsed Acute Myeloid Leukemia post allogeneic hematopoietic stem cell transplantation.

The venetoclax combined with metronomic low-dose decitabine and interferon for preventing post-transplant relapse in high-risk MDS and AML patients

The single-center retrospective analysis of steroid-free rmap regimen (ruxolitinib, montelukast, azithromycin, and pirfenidone) treating moderate-to-severe bronchiolitis obliterans syndrome (BOS).

Efficacy and prognosis of venetoclax combined with the 3+7 regimen in fit AML: A propensity score-matched cohort study

Venetoclax Plus Chidamide/Azacitidine Dual Epigenetic Target Regimen in High-Risk Acute Lymphoblastic Leukemia: Preclinical and Case Series Studies

Human IFN-α2- and PD-L1-Modified T Cells (αp-T cells) Inhibit Graft-Versus-Host Disease but Retain Anti-Leukemia Activity

Efficacy and Safety of Dose-Tailored Mitoxantrone Liposomes Combined with Cytarabine and Venetoclax in Newly Diagnosed Acute Myeloid Leukemia (Non-M3) Based on Marrow Leukemic Cellularity

Exploring Prognostic Factors of Venetoclax Combined with Azacitidine in Unfit AML Based on Real-World Data from a Chinese Population

Risk Factors for CMV Infection, Including HLA Disparity and Ptcy Transplant in the Era of Letermovir Prophylaxis

Sting-Mediated Interferon Signaling Exerts Potent Antileukemic Effects in High-Risk Myeloid and Monocytic Malignancies

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only